---
title: "Endocrine Surgery"
order: 3
category: "General Surgery"
---

# Endocrine Surgery

## Overview

Endocrine surgery encompasses operative procedures on hormone-producing glands including thyroid, parathyroid, adrenal, and neuroendocrine organs. Successful outcomes require understanding of endocrine physiology, biochemical diagnosis, surgical anatomy, and management of hormone-related complications. Most endocrine operations are now performed using minimally invasive techniques when appropriate.

## Thyroid Surgery

### Indications

#### Thyroid Nodules and Cancer

**Clinical Presentation**
- **Palpable Thyroid Nodule**: Most common presentation
- **Incidental Finding**: On imaging for other conditions
- **Compressive Symptoms**: Dysphagia, dyspnea, voice changes
- **Hyperthyroidism**: Toxic nodule, toxic multinodular goiter
- **Lymphadenopathy**: Concerning for malignancy

**Thyroid Nodule Evaluation**

**Initial Assessment**
- **TSH Level**: First test
  - **Low TSH**: Suggests autonomy, obtain thyroid scan
  - **Normal/High TSH**: Proceed with ultrasound evaluation

**Ultrasound Characteristics** (ATA Risk Stratification)
- **High Suspicion**: Solid hypoechoic, irregular margins, microcalcifications, taller-than-wide, extrathyroidal extension
- **Intermediate Suspicion**: Hypoechoic, solid, smooth margins
- **Low Suspicion**: Isoechoic or hyperechoic, solid
- **Very Low Suspicion**: Spongiform or partially cystic
- **Benign**: Pure cyst

**Fine Needle Aspiration (FNA) Biopsy**
- **Indications**: Based on size and sonographic pattern
  - High suspicion: ≥1 cm
  - Intermediate suspicion: ≥1 cm
  - Low suspicion: ≥1.5 cm
  - Very low suspicion: ≥2 cm
  - Suspicious lymph nodes: Any size

**Bethesda Classification**
- **I - Nondiagnostic** (5-10%): Repeat FNA
- **II - Benign** (60-70%): Observation
- **III - Atypia of Undetermined Significance (AUS)** (10-15%): Repeat FNA or molecular testing
- **IV - Follicular Neoplasm** (10-25%): Surgery vs. molecular testing
- **V - Suspicious for Malignancy** (50-75%): Surgery
- **VI - Malignant** (>95%): Surgery

**Molecular Testing**
- **Afirma Gene Expression Classifier**: Rule-out test (high NPV)
- **ThyroSeq**: Mutation panel
- **Use**: Indeterminate nodules (Bethesda III, IV) to guide management

#### Thyroid Cancer Types

**Differentiated Thyroid Cancer (>90%)**
- **Papillary Thyroid Cancer (PTC)** (80-85%):
  - Most common, best prognosis
  - Lymphatic spread common
  - Variants: Classic, follicular variant, tall cell (more aggressive)

- **Follicular Thyroid Cancer (FTC)** (10-15%):
  - Hematogenous spread (bone, lung)
  - Cannot diagnose on FNA (requires capsular/vascular invasion)

**Medullary Thyroid Cancer (MTC)** (3-5%)
- **Origin**: Parafollicular C cells
- **Marker**: Calcitonin
- **Sporadic** (75%): Unilateral
- **Hereditary** (25%): MEN 2A, MEN 2B, familial MTC
- **RET Proto-oncogene**: Germline mutations in hereditary

**Anaplastic Thyroid Cancer** (<2%)
- **Highly Aggressive**: Median survival 3-6 months
- **Presentation**: Rapidly enlarging neck mass
- **Management**: Multimodal, often palliative

#### Indications for Thyroidectomy

**Malignancy**
- Confirmed or suspected thyroid cancer
- High-risk nodules with inadequate biopsy

**Hyperthyroidism**
- Graves' disease (definitive treatment)
- Toxic multinodular goiter
- Toxic adenoma (alternative: radioiodine)

**Goiter**
- Compressive symptoms
- Substernal extension
- Cosmetic concerns

**Indeterminate Nodules**
- Bethesda III-IV with high-risk features
- Patient preference for diagnosis

### Preoperative Assessment

#### Clinical Evaluation
- **History**: Radiation exposure, family history (MEN syndromes)
- **Symptoms**: Compressive (dysphagia, dyspnea, orthopnea), hyperthyroid, hypothyroid
- **Neck Examination**: Thyroid size, nodularity, mobility, lymph nodes
- **Vocal Cord Assessment**: Laryngoscopy if voice changes or prior neck surgery

#### Laboratory Studies
- **TSH**: Thyroid function assessment
- **Free T4, Free T3**: If TSH abnormal
- **Thyroglobulin**: Baseline for differentiated thyroid cancer
- **Calcitonin**: If MTC suspected (elevated in MTC)
- **Calcium, PTH**: Baseline parathyroid function
- **Vitamin D**: Optimize preoperatively

**For Medullary Thyroid Cancer**
- **RET Genetic Testing**: All MTC patients
- **Screening for Pheochromocytoma** (MEN 2):
  - Plasma metanephrines
  - 24-hour urine metanephrines/catecholamines
- **Screening for Hyperparathyroidism**: Calcium, PTH

#### Imaging Studies
- **Thyroid Ultrasound**: Nodule characterization, lymph node assessment
- **CT Neck/Chest** (Without contrast): Large goiters, substernal extension
- **Laryngoscopy**: Vocal cord function (preoperative documentation)
- **Cross-sectional Imaging**: Advanced cancer for staging

### Surgical Techniques

#### Thyroid Lobectomy (Hemithyroidectomy)

**Indications**
- Bethesda III-IV nodules (diagnostic)
- Solitary nodule <4 cm, low-risk features
- Toxic adenoma
- Unilateral benign disease

**Operative Technique**

**Patient Positioning**
- Supine, shoulder roll, neck extended
- Arms tucked at sides
- Table slightly reverse Trendelenburg

**Incision**
- Cervical collar incision (Kocher incision)
- 4-6 cm, 1-2 fingerbreadths above sternal notch
- Within skin crease for cosmesis

**Surgical Steps**
1. **Skin Incision**: Through skin and platysma
2. **Subplatysmal Flaps**: Superior (thyroid notch), inferior (sternal notch)
3. **Divide Strap Muscles**: Between thyroid lobe and sternohyoid/sternothyroid (midline or lateral to thyroid)
4. **Mobilize Thyroid Lobe**: Rotate medially for exposure
5. **Ligate Middle Thyroid Vein**: Lateral to thyroid lobe
6. **Identify Recurrent Laryngeal Nerve (RLN)**:
   - **Critical**: Identify and preserve
   - **Location**: Tracheoesophageal groove
   - **Variations**: Non-recurrent RLN (0.5-1% right, rare left)
7. **Identify Parathyroid Glands**:
   - **Superior**: More consistent location (posterior superior thyroid)
   - **Inferior**: More variable (may be low or within thymic tongue)
   - **Preserve**: Blood supply (inferior thyroid artery branches)
8. **Ligate Superior Thyroid Vessels**: Close to thyroid capsule (preserve external branch of SLN)
9. **Divide Inferior Thyroid Artery Branches**: Individually, preserve parathyroid blood supply
10. **Divide Isthmus**: Clamp, divide, oversew
11. **Dissect Berry's Ligament**: Careful RLN injury area
12. **Remove Lobe**: Specimen to pathology
13. **Hemostasis**: Meticulous
14. **Closure**: Strap muscles approximated, platysma, skin

**Critical Anatomy**

**Recurrent Laryngeal Nerve**
- **Right RLN**: Recurs around subclavian artery, more oblique course
- **Left RLN**: Recurs around aortic arch, more vertical course
- **Identification Mandatory**: Prevents vocal cord paralysis
- **Neuromonitoring**: Adjunct, not substitute for visualization

**External Branch of Superior Laryngeal Nerve (EBSLN)**
- **Function**: Innervates cricothyroid muscle (voice pitch)
- **Preservation**: Ligate superior thyroid vessels close to thyroid capsule
- **Injury**: Voice fatigue, decreased range (especially singers)

**Parathyroid Glands**
- **Four Glands**: Superior and inferior on each side
- **Superior**: More consistent, posterior superior thyroid
- **Inferior**: Variable location, embryologically related to thymus
- **Blood Supply**: Inferior thyroid artery branches
- **Preservation**: Maintain blood supply, avoid direct manipulation

#### Total Thyroidectomy

**Indications**
- **Thyroid Cancer** (>1 cm, bilateral, high-risk features, node-positive)
- **MTC**: Always total thyroidectomy
- **Graves' Disease**: Definitive treatment
- **Bilateral Nodular Disease**
- **Large Goiter** (>40-60 g)

**Technique**
- Same as lobectomy, performed bilaterally
- Preserve all parathyroid glands
- If parathyroid devascularized: Autotransplant into sternocleidomastoid or forearm

**Completion Thyroidectomy**
- Performed if cancer found on final pathology after lobectomy
- **Timing**: Within 6 months (ideally <3 months)
- **Challenges**: Scar tissue, difficult RLN identification

#### Central Neck Dissection (Level VI)

**Anatomy**
- **Superior**: Hyoid bone
- **Inferior**: Innominate artery
- **Lateral**: Carotid sheaths
- **Contents**: Prelaryngeal, pretracheal, paratracheal lymph nodes

**Indications**
- **Therapeutic**: Clinically evident central neck nodes
- **Prophylactic**: Controversial
  - Consider for: T3/T4 tumors, aggressive histology, lateral neck involvement

**Technique**
- Remove lymph node packet from hyoid to innominate artery
- Preserve RLN, parathyroid glands
- Usually performed ipsilateral, bilateral if extensive disease

#### Lateral Neck Dissection

**Anatomy - Levels**
- **Level II**: Upper jugular nodes
- **Level III**: Mid jugular nodes
- **Level IV**: Lower jugular nodes
- **Level V**: Posterior triangle

**Indications**
- Biopsy-proven lateral neck metastases
- Papillary thyroid cancer (lymphatic spread)

**Technique**
- Modified radical neck dissection (levels II-V)
- Preserve: Spinal accessory nerve, internal jugular vein, sternocleidomastoid
- En bloc with thyroidectomy specimen

#### Minimally Invasive Thyroidectomy

**Endoscopic Thyroidectomy**
- Various approaches: Anterior chest, axillary, transoral
- Indications: Small nodules, cosmesis important
- Limitations: Learning curve, longer operative time

**Robotic Thyroidectomy**
- Transaxillary or transoral approach
- Improved visualization and dexterity
- No neck scar
- Cost and operative time considerations

### Postoperative Management

#### Immediate Postoperative Care

**Recovery Room**
- Airway monitoring (hematoma concern)
- Calcium supplementation if total thyroidectomy
- Pain control
- Voice assessment

**Calcium Monitoring** (Total thyroidectomy)
- **Ionized Calcium**: 4-6 hours postop, then q6-12h until stable
- **PTH Level**: Some use immediate postop PTH to predict hypocalcemia
- **Symptoms**: Perioral numbness, paresthesias, Chvostek/Trousseau signs
- **Treatment**: See hypocalcemia management below

**Drain Management**
- **Controversial**: Many surgeons no longer use drains
- **If Used**: Remove when <30 mL/day

#### Thyroid Hormone Replacement

**Levothyroxine Dosing**
- **Total Thyroidectomy**: Start 1.6-1.8 mcg/kg/day
- **Lobectomy**: Observe, start if TSH elevated
- **Thyroid Cancer**: May aim for TSH suppression based on risk

**Monitoring**
- Check TSH at 6 weeks, then adjust dose
- Goal: TSH 0.5-2.0 mIU/L (or suppressed if high-risk cancer)

#### Hypocalcemia Management

**Transient Hypocalcemia** (20-30% total thyroidectomy)
- **Etiology**: Parathyroid stunning, devascularization
- **Duration**: Resolves within 6 months

**Permanent Hypocalcemia** (1-3%)
- Persists >6 months

**Treatment**
- **Mild** (Ionized Ca 1.0-1.12 mmol/L, asymptomatic):
  - Oral calcium carbonate 1-3 g/day divided
  - Calcitriol 0.25-0.5 mcg daily

- **Moderate** (Ionized Ca 0.8-1.0 mmol/L, mild symptoms):
  - Oral calcium carbonate 3-6 g/day
  - Calcitriol 0.5-1 mcg daily

- **Severe** (Ionized Ca <0.8 mmol/L, severe symptoms):
  - IV calcium gluconate: 1-2 ampules in 50-100 mL D5W over 10 min
  - Followed by continuous infusion: 0.5-2 mg/kg/hr
  - Monitor ionized calcium q2-4h
  - Transition to oral when stable

**Long-term Management**
- Calcium with meals (citrate better absorbed than carbonate with PPI)
- Calcitriol adjusted to maintain low-normal calcium
- Monitor: Calcium, phosphate, magnesium, vitamin D
- Avoid: Hypercalciuria (risk of nephrolithiasis)

### Complications

#### Recurrent Laryngeal Nerve Injury

**Incidence**
- Transient: 3-8% (temporary paresis)
- Permanent: 0.5-2% (>6 months)

**Presentation**
- **Unilateral**: Hoarseness, breathy voice, aspiration
- **Bilateral**: Stridor, airway obstruction (may need tracheostomy)

**Diagnosis**
- Laryngoscopy: Vocal cord position and movement
- Perform if voice change postoperatively

**Management**
- **Transient**: Voice rest, speech therapy
- **Permanent Unilateral**: Medialization (injection, thyroplasty)
- **Permanent Bilateral**: Tracheostomy vs. arytenoidectomy

**Prevention**
- Identify RLN in all cases
- Gentle handling
- Neuromonitoring (adjunct)
- Avoid: Clamping, thermal injury, traction

#### Superior Laryngeal Nerve Injury (EBSLN)

**Incidence**: 5-15% (difficult to assess)

**Presentation**
- Voice fatigue
- Decreased vocal range
- Difficulty with high-pitched sounds
- More noticeable in professional voice users

**Prevention**
- Ligate superior thyroid vessels close to thyroid capsule
- Individual vessel ligation rather than mass ligation

#### Hypocalcemia
- See detailed management above
- **Prevention**:
  - Identify and preserve parathyroid glands
  - Preserve blood supply
  - Autotransplant if devascularized

#### Hematoma

**Incidence**: 0.5-2%

**Presentation**
- Neck swelling
- Respiratory distress
- Dysphagia
- Typically within 6 hours postop

**Management**
- **Expanding/Airway Compromise**:
  - Open wound at bedside immediately
  - Evacuate hematoma
  - Return to OR for formal exploration and hemostasis
- **Stable**: Observation vs. OR evacuation

**Prevention**
- Meticulous hemostasis
- Avoid hypertension postoperatively
- Consider drain in high-risk patients

#### Thyroid Storm (Rare)

**Risk Factors**
- Uncontrolled hyperthyroidism
- Inadequate preoperative preparation
- Stress of surgery

**Presentation**
- Fever >40°C
- Tachycardia, arrhythmias
- Altered mental status
- Cardiovascular collapse

**Management**
- ICU admission
- Beta-blockade: Propranolol
- Thionamides: PTU or methimazole
- Iodine: Lugol's solution (1 hour after thionamides)
- Steroids: Dexamethasone
- Supportive care: Cooling, fluids

**Prevention**
- Optimize thyroid function preoperatively (Graves' disease)
- Beta-blockade
- Consider thionamides preoperatively

### Outcomes

#### Operative Outcomes
- **Operative Time**: 60-120 minutes (lobectomy), 90-180 minutes (total)
- **Blood Loss**: Minimal (<50 mL)
- **Hospital Stay**: Same-day to overnight
- **Return to Activity**: 1-2 weeks

#### Oncologic Outcomes (Differentiated Thyroid Cancer)

**Overall Survival** (10-year)
- **Stage I**: >95%
- **Stage II**: >95%
- **Stage III**: 85-90%
- **Stage IV**: 50-70%

**Recurrence Risk Stratification (ATA)**
- **Low Risk**: T1-2, N0, no invasion, favorable histology (5-10% recurrence)
- **Intermediate Risk**: Microscopic extrathyroidal extension, vascular invasion, node-positive (20-30%)
- **High Risk**: Gross extrathyroidal extension, incomplete resection, distant metastases (50-70%)

## Parathyroid Surgery

### Indications

#### Primary Hyperparathyroidism (PHPT)

**Pathophysiology**
- **Adenoma** (80-85%): Single gland
- **Hyperplasia** (10-15%): Multiple glands
- **Carcinoma** (<1%): Rare, aggressive

**Clinical Presentation**
- **"Stones, Bones, Abdominal Groans, Psychiatric Moans"**
- **Stones**: Nephrolithiasis (20%)
- **Bones**: Osteoporosis, fractures, osteitis fibrosa cystica
- **Abdominal**: Constipation, peptic ulcer, pancreatitis
- **Psychiatric**: Depression, cognitive dysfunction
- **Many**: Asymptomatic (most common presentation)

**Biochemical Diagnosis**
- **Elevated Calcium**: Typically >10.5 mg/dL
- **Elevated or Inappropriately Normal PTH**: In setting of hypercalcemia
- **Low Phosphate**: Often present
- **Elevated 24-hour Urine Calcium**: Excludes familial hypocalciuric hypercalcemia (FHH)
- **Vitamin D**: Often low (check and replete)

**Indications for Surgery** (NIH/AES Guidelines)

**Symptomatic PHPT**: All patients

**Asymptomatic PHPT** - Surgery if ANY of:
- **Age <50 years**
- **Calcium >1 mg/dL above upper limit normal**
- **Creatinine Clearance <60 mL/min**
- **Bone Density**: T-score ≤ -2.5 at any site
- **Vertebral Fracture**: On imaging
- **24-hour Urine Calcium >400 mg** (risk of stones)
- **Nephrolithiasis or Nephrocalcinosis**: On imaging

#### Secondary Hyperparathyroidism
- **Etiology**: Chronic kidney disease, vitamin D deficiency
- **Treatment**: Medical management primarily
- **Surgery**: Refractory cases with severe symptoms

#### Tertiary Hyperparathyroidism
- **Etiology**: Autonomous parathyroid hyperfunction after renal transplant
- **Surgery**: Subtotal parathyroidectomy or total with autotransplant

### Preoperative Assessment

#### Localization Studies

**Sestamibi Scan** (Technetium-99m sestamibi)
- **Principle**: Preferential uptake by hyperfunctioning parathyroid
- **Sensitivity**: 80-90% for adenoma, lower for hyperplasia
- **SPECT/CT**: Improved anatomic localization

**Neck Ultrasound**
- **Sensitivity**: 70-80% (operator-dependent)
- **Advantages**: No radiation, identifies thyroid pathology
- **Limitations**: Deep/ectopic glands difficult to visualize

**4D-CT** (Four-dimensional CT)
- **Technique**: Multiphase contrast CT
- **Sensitivity**: 85-90%
- **Advantages**: Identifies ectopic glands
- **Disadvantages**: Radiation, contrast

**Concordance**
- Two concordant studies: High positive predictive value (>95%)
- Guides minimally invasive approach

**Failed Localization**
- 10-15% of cases
- Options: Bilateral exploration, repeat imaging, selective venous sampling

#### Laboratory Studies
- **Ionized Calcium**: More accurate than total calcium
- **PTH**: Intact PTH (ensure high-quality assay)
- **Vitamin D**: 25-OH vitamin D (replete if low)
- **24-hour Urine**: Calcium, creatinine (exclude FHH, assess stone risk)
- **Bone Density**: DEXA scan (baseline)
- **Creatinine**: Renal function assessment

#### Preoperative Optimization
- **Vitamin D Repletion**: To >30 ng/mL
- **Hydration**: Avoid dehydration
- **Bisphosphonates**: If severe osteoporosis
- **Laryngoscopy**: If prior neck surgery or voice changes

### Surgical Techniques

#### Minimally Invasive Parathyroidectomy (MIP)

**Indications**
- Single adenoma on concordant imaging
- No prior neck surgery
- No suspicion of multigland disease

**Technique**
- **Incision**: 2-3 cm centered over adenoma location
- **Targeted Dissection**: Direct approach to identified gland
- **Intraoperative PTH (IOPTH) Monitoring**:
  - Baseline: Before incision or manipulation
  - Post-excision: 5 and 10 minutes after gland removal
  - **Miami Criterion**: >50% decrease from baseline
  - **Indicates**: Successful removal of all hyperfunctioning tissue

**Advantages**
- Smaller incision
- Shorter operative time (30-45 minutes)
- Faster recovery
- Same cure rate as bilateral exploration

#### Bilateral Neck Exploration

**Indications**
- Negative or discordant localization studies
- Multigland disease suspected
- Prior failed parathyroidectomy
- Hereditary syndromes (MEN 1, MEN 2A)

**Technique**
- Standard thyroid incision (4-6 cm)
- Explore all four glands systematically
- Identify normal parathyroids (confirm with biopsy if uncertain)
- Remove enlarged gland(s)

**Four-Gland Exploration Protocol**
1. **Identify All Four Glands**: Systematic search
2. **Single Adenoma** (80-85%): Remove enlarged gland, confirm others normal
3. **Double Adenoma** (5%): Remove both enlarged glands
4. **Hyperplasia** (10-15%): Subtotal (3.5 gland) parathyroidectomy or total with autotransplant

**Ectopic Locations to Search**
- **Superior Glands**: Retroesophageal, posterior mediastinum
- **Inferior Glands**: Thymus, anterior mediastinum, thyroid
- **Intrathymic**: Requires thymectomy
- **Undescended**: Carotid sheath, high neck

#### Subtotal Parathyroidectomy

**Indications**
- Four-gland hyperplasia
- Secondary/tertiary hyperparathyroidism

**Technique**
- Remove 3.5 glands (leave ~50 mg remnant)
- Mark remnant with clip (for future imaging)
- Alternative: Total parathyroidectomy with autotransplant

#### Total Parathyroidectomy with Autotransplant

**Indications**
- Four-gland hyperplasia
- Familial hyperparathyroidism
- Renal failure patients (accessible for future removal)

**Technique**
- Remove all four glands
- Mince 50-100 mg of normal-appearing parathyroid
- Create pockets in sternocleidomastoid or forearm
- Implant tissue fragments
- Mark site with clip

**Advantages**
- Accessible location for re-exploration if recurrent
- Lower neck recurrence in hyperplasia

#### Reoperative Parathyroid Surgery

**Indications**
- Persistent hyperparathyroidism (elevated calcium <6 months postop)
- Recurrent hyperparathyroidism (elevated calcium >6 months postop)

**Challenges**
- Scar tissue
- Distorted anatomy
- Higher RLN injury risk (3-5%)

**Preoperative**
- Aggressive localization (4D-CT, PET-sestamibi, selective venous sampling)
- Surgeon with reoperative expertise

**Technique**
- Focused approach if localized
- Consider lateral approach (avoid central scar)
- Neuromonitoring essential
- Expect longer operative time

### Postoperative Management

#### Immediate Postoperative Care
- **Calcium Monitoring**: Check calcium 4-6 hours postop
- **Symptoms**: Monitor for hypocalcemia symptoms
- **Diet**: Regular diet, calcium-rich foods
- **Discharge**: Usually same day

#### Hungry Bone Syndrome

**Definition**
- Rapid uptake of calcium/phosphate into bone after PTH correction
- Severe, prolonged hypocalcemia

**Risk Factors**
- Severe preoperative hyperparathyroidism
- Marked bone disease
- High preoperative alkaline phosphatase
- Large adenomas (>2 g)

**Presentation**
- Symptomatic hypocalcemia despite supplementation
- May require IV calcium
- Hypomagnesemia, hypophosphatemia

**Management**
- Aggressive oral calcium (3-6 g/day)
- Calcitriol (1-3 mcg/day)
- Magnesium supplementation
- May need IV calcium infusion
- Gradual taper over weeks to months

#### Follow-up

**Short-term (1-2 weeks)**
- Calcium, PTH, vitamin D levels
- Assess for hypocalcemia
- Pathology review

**Long-term**
- Calcium and PTH at 6 months, then annually
- Repeat DEXA in 1-2 years (expect improvement)
- Screen for recurrence

### Complications

#### Hypocalcemia
- **Transient** (10-30%): Resolves within weeks
- **Permanent** (<1% single adenoma, 3-5% hyperplasia)
- **Management**: See thyroid section

#### Recurrent Laryngeal Nerve Injury
- **Risk**: Lower than thyroidectomy (0.5-1%)
- **Prevention**: Identify RLN, especially in reoperations

#### Persistent Hyperparathyroidism (5-10%)
- **Definition**: Elevated calcium <6 months postop
- **Causes**: Missed adenoma, ectopic gland, multigland disease
- **Management**: Re-localization and reoperation

#### Recurrent Hyperparathyroidism (1-5%)
- **Definition**: Elevated calcium >6 months after normalization
- **Causes**: New adenoma, hyperplasia, parathyroid carcinoma
- **Management**: Re-localization and reoperation

#### Hematoma (<1%)
- Same management as thyroid surgery

### Outcomes

#### Success Rates
- **Single Adenoma**: 95-98% cure rate
- **Hyperplasia**: 85-90% cure rate
- **Reoperative**: 70-85% cure rate

#### Biochemical Resolution
- Calcium normalizes immediately (may have transient hypocalcemia)
- PTH normalizes within 10 minutes (IOPTH)

#### Symptom Improvement
- **Kidney Stones**: Reduced recurrence (80% improvement)
- **Bone Density**: Improves 5-10% over 1-2 years
- **Neuropsychiatric**: Variable improvement
- **Quality of Life**: Significant improvement even in "asymptomatic" patients

## Adrenal Surgery

### Indications

#### Adrenal Incidentalomas

**Definition**: Adrenal mass >1 cm discovered incidentally on imaging

**Prevalence**: 4-7% on abdominal CT

**Evaluation**

**Biochemical Testing** (ALL adrenal masses)
1. **1 mg Dexamethasone Suppression Test**: Screen for subclinical Cushing's
2. **Plasma Metanephrines or 24-hour Urine Metanephrines/Catecholamines**: Pheochromocytoma
3. **If Hypertensive or Hypokalemic**: Aldosterone/renin ratio (hyperaldosteronism)

**Imaging Characteristics (Unenhanced CT)**
- **<10 HU**: Lipid-rich adenoma (benign)
- **>10 HU**: Further characterization needed
- **Washout Characteristics**: Delayed contrast washout suggests adenoma

**Indications for Surgery**
- **Functioning Tumor**: Any size
- **Size >4 cm**: Increased malignancy risk (25%)
- **Growth**: >1 cm over 1 year
- **Suspicious Features**: Irregular, heterogeneous, high HU, poor washout

#### Pheochromocytoma

**Clinical Presentation**
- **Classic Triad**: Headache, palpitations, diaphoresis
- **Hypertension**: Sustained or paroxysmal
- **Other**: Anxiety, tremor, pallor
- **"Rule of 10s"**: 10% bilateral, 10% extra-adrenal, 10% malignant, 10% familial

**Biochemical Diagnosis**
- **Plasma Free Metanephrines**: Sensitivity >95%
- **24-hour Urine Metanephrines/Catecholamines**: Confirmatory
- **Chromogranin A**: Elevated

**Imaging**
- **CT/MRI**: Localization (MRI preferred, T2 hyperintense)
- **MIBG Scan**: Functional imaging, metastatic workup
- **FDG-PET**: Malignant pheochromocytoma

**Genetic Testing** (Considered in All)
- **Hereditary Syndromes**: MEN 2, VHL, NF1, paraganglioma syndromes
- **Germline Mutations**: 25-40% of pheochromocytomas

**Preoperative Management** (CRITICAL)
- **Alpha-Blockade**: Phenoxybenzamine 10-20 mg BID, titrate up over 7-14 days
- **Beta-Blockade**: ONLY after adequate alpha blockade (prevents unopposed alpha)
- **Volume Expansion**: High sodium diet, fluids
- **Goal**: Normotension, HR <100, no orthostatic symptoms

#### Primary Aldosteronism (Conn's Syndrome)

**Clinical Presentation**
- **Hypertension**: Often resistant to treatment
- **Hypokalemia**: May be mild or absent
- **Metabolic Alkalosis**

**Screening**
- **Aldosterone/Renin Ratio**: >20-30 suggests primary aldosteronism

**Confirmatory Testing**
- **Saline Suppression Test**: Aldosterone fails to suppress
- **Oral Sodium Loading**: 24-hour urine aldosterone remains elevated

**Subtype Differentiation** (Critical for surgical decision)
- **Adrenal CT**: Identify unilateral vs. bilateral masses
- **Adrenal Vein Sampling** (AVS):
  - **Gold Standard**: Lateralization of aldosterone production
  - **Interpretation**: Lateralization index >4 indicates unilateral source
  - **Indications**: Age <40 or bilateral nodules on CT

**Surgical Candidacy**
- **Unilateral Disease**: Surgery curative
- **Bilateral Hyperplasia**: Medical management (spironolactone)

#### Adrenal Cortical Carcinoma (ACC)

**Presentation**
- Functioning (60%): Cushing's, virilization, mixed
- Non-functioning (40%): Abdominal mass, pain
- Advanced stage at diagnosis common

**Imaging**
- **Large**: Often >6 cm
- **Suspicious Features**: Irregular, heterogeneous, necrosis, invasion, metastases

**Management**
- **Surgical Resection**: Only curative treatment
- **En Bloc Resection**: Involved organs
- **Open Approach**: Preferred for large/invasive tumors
- **Adjuvant Mitotane**: Postoperatively

### Preoperative Assessment

#### Clinical Evaluation
- **Hormone Excess Symptoms**: Cushing's, pheochromocytoma, hyperaldosteronism
- **Malignancy Risk Assessment**: Size, growth rate, imaging features
- **Fitness for Surgery**: Especially cardiovascular risk

#### Imaging
- **Dedicated Adrenal CT**: Unenhanced + contrast with washout
- **MRI**: T2-weighted for pheochromocytoma
- **Metastatic Workup**: Chest CT if malignancy concern

### Surgical Techniques

#### Laparoscopic Adrenalectomy (Standard Approach)

**Indications**
- Benign adrenal tumors <8 cm
- Pheochromocytoma (experienced surgeons)
- Selected cases of ACC <5 cm without invasion

**Contraindications**
- Invasion of adjacent structures
- Large ACC with high malignancy suspicion
- Inability to tolerate pneumoperitoneum

**Approaches**

**Lateral Transabdominal** (Most Common)
- **Positioning**: Lateral decubitus, flexed
- **Ports**: 3-4 ports
- **Advantages**: Excellent exposure, familiar anatomy
- **Left**: Mobilize spleen/pancreas, identify adrenal vein (drains to renal vein)
- **Right**: Mobilize liver, IVC exposure, adrenal vein directly to IVC (short!)

**Posterior Retroperitoneal**
- **Positioning**: Prone, jack-knife
- **Advantages**: No intraperitoneal entry, bilateral simultaneous
- **Disadvantages**: Limited space, unfamiliar anatomy

**Operative Steps (Left Lateral Transabdominal)**
1. **Positioning**: Right lateral decubitus, flexed, secured
2. **Port Placement**: Subcostal, 3-4 ports
3. **Mobilize Spleen and Tail of Pancreas**: Medially
4. **Incise Lienorenal Ligament**
5. **Identify Adrenal Gland**: Superior to kidney
6. **Dissect Adrenal**: Circumferentially
7. **Ligate Adrenal Vein**: Early (especially pheochromocytoma), to renal vein
8. **Complete Dissection**: Free adrenal from kidney
9. **Specimen Removal**: Endobag
10. **Hemostasis**: Inspect adrenal bed
11. **Closure**

**Operative Steps (Right Lateral Transabdominal)**
1. **Positioning**: Left lateral decubitus
2. **Mobilize Liver**: Triangular ligament division
3. **Expose IVC and Adrenal**
4. **Ligate Adrenal Vein**: Very short, directly to IVC (injury risk!)
5. **Complete Dissection**: Free from kidney and liver
6. **Remove Specimen**

**Pheochromocytoma-Specific Considerations**
- **Adequate Alpha Blockade**: Essential
- **Minimal Manipulation**: Until vein secured
- **Early Venous Ligation**: Prevent catecholamine surge
- **Monitoring**: Arterial line, avoid catecholamine-releasing drugs
- **Hypertension**: Short-acting agents (phentolamine, nicardipine)
- **Hypotension**: After venous ligation, volume and pressors

#### Open Adrenalectomy

**Indications**
- Large tumors (>8-10 cm)
- Adrenal cortical carcinoma
- Invasion of adjacent structures
- Conversion from laparoscopic

**Approaches**
- **Anterior Transabdominal**: Large masses, bilateral
- **Flank**: Unilateral, smaller masses
- **Thoracoabdominal**: Very large, superior extension

**Technique (Anterior)**
- Midline or bilateral subcostal incision
- Complete mobilization
- En bloc resection if malignancy (kidney, IVC, liver if involved)
- Wide margins

### Postoperative Management

#### General Care
- **Hospital Stay**: 1-2 days laparoscopic, 3-5 days open
- **Pain Management**: Minimally invasive approach, less pain
- **Diet**: Advance as tolerated
- **Activity**: Ambulate early, return to full activity in 2-4 weeks

#### Hormone Replacement

**After Bilateral Adrenalectomy or Adrenal Insufficiency**
- **Glucocorticoid Replacement**:
  - Hydrocortisone 15-20 mg AM, 5-10 mg afternoon
  - Increase during stress/illness
- **Mineralocorticoid Replacement**:
  - Fludrocortisone 0.05-0.1 mg daily
- **Adrenal Crisis Prevention**: Medical alert bracelet, stress dosing education

**After Unilateral Adrenalectomy for Cushing's**
- Temporary glucocorticoid replacement (HPA axis suppression)
- Taper as HPA axis recovers (weeks to months)
- Monitor cortisol and ACTH

#### Pheochromocytoma-Specific
- **Hypotension**: Common after tumor removal (stop alpha blockade)
- **Fluid Resuscitation**: Generous IV fluids
- **Monitor**: Glucose (catecholamine-induced hyperglycemia resolves)
- **Follow-up**: 24-hour urine metanephrines at 2-4 weeks (exclude residual/metastatic)
- **Genetic Counseling**: If hereditary syndrome

#### Primary Aldosteronism
- **Hyperkalemia**: May occur after unilateral adrenalectomy (cessation of aldosterone excess)
- **Hypertension**: May persist (30-50% still need antihypertensives)
- **Spironolactone**: Continue temporarily, wean as tolerated

### Complications

#### Intraoperative
- **Hemorrhage** (2-5%): Adrenal vein injury (especially right)
- **IVC Injury** (<1%): Right adrenalectomy
- **Bowel/Spleen/Pancreas Injury** (<1%): During mobilization
- **Hypertensive Crisis** (Pheochromocytoma): Inadequate blockade, manipulation

#### Postoperative
- **Adrenal Insufficiency**: Bilateral or Cushing's surgery
- **Hypotension**: Pheochromocytoma (post-resection)
- **Persistent Hypertension**: Aldosteronoma (30-50%)
- **Pneumothorax** (1-2%): Apical dissection

### Outcomes

#### Pheochromocytoma
- **Cure Rate**: >95% for benign tumors
- **Hypertension**: Resolves in 70-80%, improves in most
- **Recurrence**: 5-10% (higher if hereditary)
- **Malignant**: 10-year survival 40-60%

#### Primary Aldosteronism
- **Cure of Hypertension**: 30-60%
- **Improvement**: 70-90% fewer medications or better control
- **Hypokalemia**: Resolves in >95%

#### Adrenal Cortical Carcinoma
- **Complete Resection**: Only chance for cure
- **5-Year Survival**: Stage I-II 50-60%, Stage III-IV <20%
- **Recurrence**: Common even after resection

## Key Points

### Thyroid Surgery
- **Vocal cord assessment** essential preoperatively and postoperatively
- **RLN identification** mandatory to prevent permanent vocal cord paralysis
- **Parathyroid preservation** critical during total thyroidectomy
- **Critical view of safety**: Similar concept to cholecystectomy but for RLN and parathyroids
- **Hypocalcemia management**: Aggressive calcium and calcitriol replacement
- **Thyroid cancer outcomes**: Excellent prognosis for differentiated thyroid cancer (>95% 10-year survival for early stage)

### Parathyroid Surgery
- **Localization studies** (sestamibi, ultrasound, 4D-CT) guide minimally invasive approach
- **Intraoperative PTH** monitoring confirms biochemical cure during MIP
- **Vitamin D repletion** essential preoperatively
- **Hungry bone syndrome**: Risk after correction of severe hyperparathyroidism
- **High cure rates**: >95% for single adenoma with experienced surgeon
- **Quality of life improvement** even in "asymptomatic" patients

### Adrenal Surgery
- **Biochemical testing** mandatory for all adrenal masses (functioning vs. non-functioning)
- **Pheochromocytoma**: Adequate alpha-blockade 7-14 days preoperatively (prevent hypertensive crisis)
- **Adrenal vein sampling** determines laterality in primary aldosteronism
- **Laparoscopic approach** standard for benign tumors <8 cm
- **Early adrenal vein ligation** during pheochromocytoma resection
- **Right adrenal vein** very short, drains directly to IVC (injury risk)

## References

1. **American Thyroid Association (ATA) Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer** (2015). Thyroid. 2016;26(1):1-133.

2. Haugen BR, et al. **2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer**. Thyroid. 2016;26(1):1-133.

3. **NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma** (Version 2.2024). National Comprehensive Cancer Network.

4. Bilezikian JP, et al. **Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism** (4th Workshop). J Clin Endocrinol Metab. 2014;99(10):3561-3569.

5. Wilhelm SM, et al. **The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism**. JAMA Surg. 2016;151(10):959-968.

6. Lenders JWM, et al. **Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline**. J Clin Endocrinol Metab. 2014;99(6):1915-1942.

7. Funder JW, et al. **The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment - An Endocrine Society Clinical Practice Guideline**. J Clin Endocrinol Metab. 2016;101(5):1889-1916.

8. Fassnacht M, et al. **European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults**. Eur J Endocrinol. 2018;179(4):G1-G46.

9. Berber E, Siperstein A. **Robotic and Laparoscopic Adrenal Surgery**. Surg Clin North Am. 2016;96(3):519-533.

10. Randolph GW, et al. **The Voice Outcome After Thyroid Surgery (VOICE) Consensus Statement**. Laryngoscope. 2013;123(9):2371-2382.
